AT2R Agonist, Compound 21, Is Reno-Protective Against Type 1 Diabetic Nephropathy

The hemodynamic and nonhemodynamic effects of angiotensin II on diabetic complications are considered to be primarily mediated by the angiotensin II type 1 receptor subtype. However, its biological and functional effect mediated through the angiotensin II type 2 receptor subtype is still unclear. Activation of the angiotensin II type 2 receptors has been postulated to oppose angiotensin II type 1 receptor–mediated actions and thus attenuate fibrosis. This study aimed to elucidate the reno-protective role of the novel selective angiotensin II type 2 receptor agonist, Compound 21, in an experimental model of type 1 diabetic nephropathy. Compound 21 treatment significantly attenuated diabetes mellitus–induced elevated levels of cystatin C, albuminuria, mesangial expansion, and glomerulosclerosis in diabetic mice. Moreover, Compound 21 markedly inhibited the expression of various proteins implicated in oxidative stress, inflammation, and fibrosis, in association with decreased extracellular matrix production. These findings demonstrate that monotherapy of Compound 21 is protective against the progression of experimental diabetic nephropathy by inhibiting renal oxidative stress, inflammation, and fibrosis.

[1]  R. Summers,et al.  Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. , 2014, Kidney international.

[2]  T. Hussain,et al.  AT2 receptor protects high sodium‐induced decrease in ACE2/Mas receptor expression and increase in blood pressure in obese rats (1136.8) , 2014 .

[3]  Li Yu,et al.  Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection. , 2014, Endocrinology.

[4]  B. Dahlöf,et al.  Novel Therapeutics in Renal Diseases Prevention of diabetic nephropathy by compound 21 , selective agonist of angiotensin type 2 receptors , in Zucker diabetic fatty rats , 2014 .

[5]  G. Appel.  Detecting and controlling diabetic nephropathy: What do we know? , 2013, Cleveland Clinic Journal of Medicine.

[6]  T. Hussain,et al.  Proximal Tubule Angiotensin AT2 Receptors Mediate an Anti-Inflammatory Response via Interleukin-10: Role in Renoprotection in Obese Rats , 2013, Hypertension.

[7]  H. Ren,et al.  Angiotensin II AT2 receptor decreases AT1 receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar–Kyoto rats , 2012, Journal of hypertension.

[8]  E. Schiffrin,et al.  Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats , 2012, Hypertension.

[9]  髙宮 良美.  Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice , 2012 .

[10]  Y. Chen,et al.  Angiotensin II Type II Receptor Deficiency Accelerates the Development of Nephropathy in Type I Diabetes via Oxidative Stress and ACE2 , 2011, Experimental diabetes research.

[11]  G. Wolf,et al.  Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. , 2011, Journal of the American Society of Nephrology : JASN.

[12]  L. Moore,et al.  Role of the AT2 receptor in modulating the angiotensin II contractile response of the uterine artery at mid-gestation , 2011, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[13]  H. Siragy,et al.  Angiotensin AT2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension , 2011, Hypertension.

[14]  T. Hussain,et al.  High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells , 2010, Molecular and Cellular Biochemistry.

[15]  H. Siragy.  The angiotensin II type 2 receptor and the kidney , 2010, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[16]  Merlin C. Thomas,et al.  The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice , 2009, Diabetologia.

[17]  Antony Vinh,et al.  AT2 receptors: Functional relevance in cardiovascular disease , 2008, Pharmacology & Therapeutics.

[18]  S. Twigg,et al.  Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers , 2008, Vascular health and risk management.

[19]  G. Wolf,et al.  Angiotensin II-induced reactive oxygen species and the kidney. , 2007, Journal of the American Society of Nephrology : JASN.

[20]  A. Parrish,et al.  Role of matrix metalloproteinases in renal pathophysiologies. , 2007, American journal of physiology. Renal physiology.

[21]  V. Pérez-Alvarez,et al.  Renal Angiotensin-II Receptors Expression Changes in a Model of Preeclampsia , 2007, Hypertension in pregnancy.

[22]  I. Darby,et al.  Fibroblast differentiation in wound healing and fibrosis. , 2007, International review of cytology.

[23]  H. van Goor,et al.  Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent Hypertension , 2006, Journal of Pharmacology and Experimental Therapeutics.

[24]  R. Carey.  Cardiovascular and Renal Regulation by the Angiotensin Type 2 Receptor: The AT2 Receptor Comes of Age , 2005, Hypertension.

[25]  N. Vaziri,et al.  Upregulation of Angiotensin II Type 1 Receptor, Inflammatory Mediators, and Enzymes of Arachidonate Metabolism in Obese Zucker Rat Kidney: Reversal by Angiotensin II Type 1 Receptor Blockade , 2005, Circulation.

[26]  N. Manabe,et al.  Decreased expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in the kidneys of hereditary nephrotic (ICGN) mice. , 2005, The Journal of veterinary medical science.

[27]  Anders Karlén,et al.  Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. , 2004, Journal of medicinal chemistry.

[28]  K. P. Singh,et al.  Dynamics of collagen, MMP and TIMP gene expression during the granulomatous, fibrotic process induced by Schistosoma mansoni eggs , 2004, Annals of tropical medicine and parasitology.

[29]  Merlin C. Thomas,et al.  Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.

[30]  O. Jöhren,et al.  Cardiovascular and renal function of angiotensin II type-2 receptors. , 2004, Cardiovascular research.

[31]  D. Weihrauch,et al.  Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. , 2004, American journal of physiology. Renal physiology.

[32]  A. Phillips,et al.  Role of Connective Tissue Growth Factor in Mediating Hypertrophy of Human Proximal Tubular Cells Induced by Angiotensin II , 2003, American Journal of Nephrology.

[33]  R. Widdop,et al.  Angiotensin AT2 receptors: cardiovascular hope or hype? , 2003, British journal of pharmacology.

[34]  Hernan Rincon-Choles,et al.  Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. , 2002, Kidney international. Supplement.

[35]  E. Vivian,et al.  Pharmacologic management of diabetic nephropathy. , 2002, Clinical therapeutics.

[36]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[37]  H. Lother,et al.  The Angiotensin II AT2 Receptor Is an AT1Receptor Antagonist* , 2001, The Journal of Biological Chemistry.

[38]  J. McMullen,et al.  Selective down-regulation of AT2 receptors in uterine arteries from pregnant ewes given 24-h intravenous infusions of angiotensin II , 2001, Regulatory Peptides.

[39]  F. Thaiss,et al.  Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. , 2001, Kidney international.

[40]  S. Ito,et al.  Angiotensin II type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vasodilatation. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  M. Kinoshita,et al.  Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.

[42]  S. Klahr,et al.  Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. , 1999, American journal of physiology. Renal physiology.

[43]  B. Brüne,et al.  Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. , 1998, The American journal of physiology.

[44]  T. Inagami,et al.  Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. , 1998, Kidney international.

[45]  G. Wolf,et al.  Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. , 1995, Kidney international.

[46]  R. Morishita,et al.  The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.

[48]  Y Wanaka,et al.  [Angiotensin II]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[49]  E. Schulze-Lohoff,et al.  Role of ornithine decarboxylase for proliferation of mesangial cells in culture. , 1991, Kidney international.

[50]  P. Gallop,et al.  Posttranslational protein modifications, with special attention to collagen and elastin. , 1975, Physiological reviews.